Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 16/20 | 0.50 |
| ▸ | MMP9 | P14780 | 16/20 | 0.50 |
| ▸ | MMP3 | P08254 | 5/20 | 0.50 |
| ▸ | MMP13 | P45452 | 4/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7861873 | 0.96 | GSK3B (0.59) | GSK3BMMP2MMP9MMP3MMP13 | |
| SCHEMBL6291932 | 0.89 | MMP2 (0.48) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7378575 | 0.88 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4654577 | 0.88 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7347186 | 0.88 | MMP2 (0.59) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7865124 | 0.88 | TSHR (0.58) | GSK3BMMP2MMP9MMP3MMP13 | |
| SCHEMBL6296070 | 0.87 | MMP2 (0.47) | GSK3BMMP2MMP9MMP3MMP13 | |
| SCHEMBL8480599 | 0.84 | MMP2 (0.48) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6292109 | 0.84 | MMP2 (0.51) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL4318837 | 0.84 | MMP2 (0.56) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900194-B1 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2005-05-31 | — | — | US | disclosed |